Lottie has been fighting high-risk neuroblastoma since she was 2 ½. A happy little girl with a sweet wilful nature, she loves to create and adores anything pink and sparkly. 

Now 4 years old, Lottie has been responding well to frontline standard treatment and is due to finish immunotherapy mid-September 2017. This will mark the end of her treatment in the UK, at which point it is hoped that her end-of-treatment scans will show no evidence of disease.

Then, to keep Lottie in remission and help prevent relapse, which she is more susceptible to because her primary tumour had MYCN markers, her next step will be to access the Bivalent Vaccine clinical trial at Memorial Sloan Kettering Cancer Center, New York. Her family and treating team have identified this as the best option to help keep Lottie neuroblastoma free.

Lottie and her family remain ever positive and prepared to fight and have been appealing for your help to raise £155k to access the trial; cover the associated costs (e.g. travel and accommodation); and to ensure a contingency for any unforeseen complications.

Thanks to the incredible support they’ve received, the family met their fundraising target on 15th September. They now have enough funds in place for Lottie to access the treatment, which pending confirmation of her eligibility, they hope she can do very soon.

“We will never leave her side. We’ll never give up, we’ll fight with her, for her, and next to her.” Lottie’s parents, Charlotte and Dave. 

Read more about Lottie’s story here and follow her journey via Facebook, Twitter and Instagram.